^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Cancer

    Related cancers:
    1d
    IMMUNO-SUP: Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy (clinicaltrials.gov)
    P=N/A, N=135, Completed, Institut Paoli-Calmettes | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    1d
    CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Roswell Park Cancer Institute
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Lumakras (sotorasib) • Krazati (adagrasib) • CimaVax EGF (EGF-PTI)
    1d
    SECURE: Barriers and Facilitators of Persistence With Adjuvant Osimertinib (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, AstraZeneca
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Tagrisso (osimertinib)
    1d
    KontRASt-02: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=95, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    docetaxel • opnurasib (JDQ443)
    1d
    COMPEL: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=98, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
    1d
    RTOG-1106: Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=138, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • paclitaxel
    1d
    INSPECT: InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology (clinicaltrials.gov)
    P=N/A, N=30, Completed, Sensome | Recruiting --> Completed
    Trial completion
    1d
    KRASCENDO 3: A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Hoffmann-La Roche
    New P3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • divarasib (RG6330)
    1d
    KontRASt-06: Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2026 --> Nov 2027
    Trial completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12
    |
    opnurasib (JDQ443)
    1d
    A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Kumquat Biosciences Inc.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12 • KRAS G12S
    1d
    AB1MALTISC-UK: Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK (clinicaltrials.gov)
    P=N/A, N=18, Recruiting, Creo Medical Limited | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    1d
    START-lung: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (clinicaltrials.gov)
    P2, N=48, Recruiting, ETOP IBCSG Partners Foundation | Not yet recruiting --> Recruiting | N=30 --> 48
    Enrollment open • Enrollment change • Trial initiation date
    |
    Imdelltra (tarlatamab-dlle)